Glycopyrronium Bromide/Rivastigmine

格隆溴铵/卡巴拉汀

Report date: 2022/01/14 13:23:58

Base Information

Drug NameGlycopyrronium Bromide/Rivastigmine
Drug Alias NameGlycopyrrolate+rivastigmine重酒石酸卡巴拉汀/格隆溴铵Rivastigmine Tartrate/Glycopyrronium Bromide卡巴拉汀+格隆溴铵Rivastigmine+Glycopyrrolate +[12] 
ClassificationSmall molecules
Mechanisms of ActionAcetylcholinesterase inhibitorsMuscarinic acetylcholine receptor antagonists
TargetsMuscarinic acetylcholine receptorAcetylcholinesterase
Therapy Area/IndicationsAlzheimer DiseaseLewy Body Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsYes Rivastigmine TartrateGlycopyrronium Bromide
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesSio Gene Therapies IncQaam Pharmaceuticals
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesQaam PharmaceuticalsSio Gene Therapies Inc
Active IndicationsN/A
Inactive IndicationsAlzheimer DiseaseLewy Body Disease

Other Information

ATC CodeN/A
Related LinksN/A